Clinical Trial

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

Study acronym: ARTEMIDELung04
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.
Protocol Amendment History 2 changes
notable Trial sites expanded: 296 -> 304 locations 2026-08-04
notable Trial sites expanded: 288 -> 294 locations 2026-04-25
Trial Details
NCT Number NCT06868277
Lead Sponsor AstraZeneca
Conditions Carcinoma, Non-Small Cell Lung
Enrollment 830 participants
Start Date 2025-04-10
Primary Completion 2030-01-17 (estimated)
Study Completion 2030-12-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-03